Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
| Autor: | Lagging, Martin, Langeland, Nina, Pedersen, Court, Färkkilä, Martti, Buhl, Mads Rauning, Mørch, Kristine, Dhillon, Amar P, Alsiö, Asa, Hellstrand, Kristoffer, Westin, Johan, Norkrans, Gunnar, Study Group, NORDynamIC |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Male
Hepacivirus medicine.disease_cause Gastroenterology Polyethylene Glycols chemistry.chemical_compound 0302 clinical medicine Genotype education.field_of_study biology Interferon Alfa-2a virus diseases Middle Aged Recombinant Proteins 3. Good health Treatment Outcome 030220 oncology & carcinogenesis RNA Viral 030211 gastroenterology & hepatology Drug Therapy Combination Female Peginterferon alfa-2a medicine.drug Adult medicine.medical_specialty Hepatitis C virus Population Alpha interferon Interferon alpha-2 Antiviral Agents Sensitivity and Specificity Drug Administration Schedule 03 medical and health sciences Predictive Value of Tests Internal medicine Ribavirin medicine Humans education Hepatology business.industry Interferon-alpha Hepatitis C Chronic biology.organism_classification Surgery chemistry business |
| Zdroj: | Lagging, M, Langeland, N, Pedersen, C, Färkkilä, M, Buhl, M R, Mørch, K, Dhillon, A P, Alsiö, A, Hellstrand, K, Westin, J, Norkrans, G & Study Group, NORDC 2008, ' Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection ', Hepatology, vol. 47, no. 6, pp. 1837-1845 . https://doi.org/10.1002/hep.22253 Lagging, M, Langeland, N, Pedersen, C, Färkkilä, M, Buhl, M R, Mørch, K, Dhillon, A P, Alsiö, A, Hellstrand, K, Westin, J, Norkrans, G & NORDynamIC Study Group 2008, ' Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection ', Hepatology, vol. 47, no. 6, pp. 1837-45 . https://doi.org/10.1002/hep.22253 |
| DOI: | 10.1002/hep.22253 |
| Popis: | Udgivelsesdato: 2008-Jun Previous trials investigating the efficacy of treatment durations shorter than the standard of 24 weeks for chronic hepatitis C virus (HCV) genotype 2/3 infections have yielded discordant results. The aims of this investigator-initiated phase III study were to compare the efficacy of 12 or 24 weeks of treatment and to identify patients suitable for short-term therapy. Three hundred eighty-two genotype 2/3-infected patients [intention-to-treat (ITT) population] at 31 centers in Denmark, Finland, Norway, and Sweden were randomized to 12 or 24 weeks of peginterferon alpha-2a (180 microg/week) plus ribavirin (800 mg/day). Twelve weeks of therapy was inferior to 24 weeks in the ITT population (sustained viral response [SVR] rates: 59% versus 78%, P < 0.0001) and in the subgroups of patients infected with genotype 2 (56% versus 82%, P = 0.006) or 3 (58% versus 78%, P = 0.0015). These differences were observed regardless of the fibrosis stage. Age and HCV-RNA levels on days 7 and 29 were independent predictors of SVR. Short-term treatment was useful in patients < 40 years old, especially if HCV-RNA was undetectable on day 29, and also in patients > or = 40 years old, provided that HCV-RNA was below 1000 IU/mL on day 7 in addition to being undetectable on day 29. If neither of these two criteria were met for patients > or = 40 years old, 24 weeks of therapy was superior (P < 0.0001). CONCLUSION: Peginterferon/ribavirin treatment for 12 weeks in HCV genotype 2/3 infection is overall inferior to 24 weeks of treatment but may be useful in some patients with a rapid initial clearance of virus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|